Interest of the Nefopam and PCA Morphine Combination for Postoperative Analgesia in Patients Undergoing Colon Surgery (NEFOPAM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Gard
-
Nîmes, Gard, France, 30029
- CHU de Nîmes
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patient with a score ASA between I and III
- Patient scheduled for elective major abdominal surgery (by laparotomy) for cancer or diverticulosis
- Patient that signed the consent form
Exclusion Criteria:
- - Patient treated in emergency situation
- Patient with chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Patient that needs a surgery for restoration of continuity
- Patient pregnant, breastfeeding, or during periods of genital activity using no contraception.
- Patient with contraindications to nefopam, morphine, or paracetamol
- Patient with chronic obstructive pulmonary disease, renal or severe hepatic impairment
- Patient under analgesics treatment
- Patient who participated in a clinical study in the previous 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: control group
|
The Control group received 120 mg placebo infusion (saline solution) by continuous iv infusion over the study period (48h).
|
|
Experimental: Nefopam group
|
The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Estimate morphine consumption
Time Frame: over 48 hours
|
mg
|
over 48 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jacques RIPART, Dr, Nîmes University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Intestinal Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Colorectal Neoplasms
- Intestinal Neoplasms
- Colonic Diseases
- Colonic Neoplasms
- Diverticulosis, Colonic
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Pharmaceutical Preparations
- Crystalloid Solutions
- Isotonic Solutions
- Solutions
- Oxazocines
- Azocines
- Nefopam
- Saline Solution
Other Study ID Numbers
Other Study ID Numbers
- PHRC-I/2003/JYL-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.